A Phase III clinical study switching paroxysmal nocturnal hemoglobinuria (PNH) patients from eculizumab treatment to Coversin.
Phase of Trial: Phase III
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Coversin (Primary) ; Eculizumab
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Acronyms ASSET
- 08 Dec 2017 According to an Akari media release, company plans to initiate this trial in the second half of 2018 and will include Soliris switch patients.
- 22 Sep 2017 New trial record